Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): Outcome analysis from a single institution

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1316-1325

  Hinz, Torsten ^a   Ahmadzadehfar, Hojjat ^a   Wierzbicki, Anja ^a   Hoeller, Tobias ^a   Wenzel, Joerg ^a   Biersack, Hans J ^a   Bieber, Thomas ^a   Schmid Wendtner, Monika H ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Interdisciplinary Oncology Center (IOC) Munich   (Germany)

Author keywords

Follow up; High risk melanoma; Sentinel lymph node biopsy; Staging prognosis

Indexed keywords

NANOCOLL TC 99M;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DERMATOLOGY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; SKINFOLD THICKNESS; TUMOR VOLUME; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84865524121     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2139-3     Document Type: Article

References (39)

1. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol. 2009;27:6199-206.
2. Ross MI. Sentinel node biopsy for melanoma: an update after two decades of experience. Semin Cutan Med Surg. 2010;29:238-48.
3. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17. (Pubitemid 44465459)
4. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15:670-3.
5. Vuylsteke RJ, van Leeuwen PA. Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long term follow-up results. J Clin Oncol. 2003;21:1057-65. (Pubitemid 46594135)
6. Hinz T, Ahmadzadehfar H, Wierzbicki A, Höller T, Wenzel J, Biersack HJ, et al. Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up. Eur J Nucl Med Mol Imaging. 2012;39:581-8
7. Perrott RE, Glass LF, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003;49:567-88. (Pubitemid 37210267)
8. Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (≥ 4mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10:408-15. (Pubitemid 40486939)
9. Jacobs IA, Chang CK, Salti GI. Role of Sentinel lymph node biopsy in patients with thick (> 4mm) primary melanoma. Ann Surg. 2004;70:59-62.
10. Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or 0 4mm) melanomas. J Dtsch Dermatol Ges. 2008;6:198-203. (Pubitemid 351361065)
11. Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137-41. (Pubitemid 41779567)
12. Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002;9:719-22.
13. Essner R, Chung MH, Bleicher R, Hsueh E,Wanek L, Morton DL. Prognostic implications of thick (≥4mm) melanoma in the era ofintraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9:754-61.
14. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-34. (Pubitemid 32786275)
15. Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK. Clinical node-negative thick melanoma. Arch Surg. 2002;137:291-5. (Pubitemid 34207988)
16. Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520-9. (Pubitemid 46606483)
17. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol. 1992;8:400-14.
18. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol. 2003;10:575-81. (Pubitemid 40486923)
19. Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29:305-17. (Pubitemid 40321965)
20. Topar G, Eisendle K, Zelger B, Fritsch P. Sentinel lymph node status in melanoma: a valuable prognostic factor? Br J Dermatol. 2006;154:1080-7. (Pubitemid 43727388)
21. Rondelli F, Vedovati MC, Becattini C, Tomassini GM, Messina S, Noya G, et al. Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis. J Eur Acad Dermatol Venereol. 2012;26:560-5.
22. Mansfield PF, Lee JE, Balch CM. Cutaneous melanoma: current practise and surgical controversies. Curr Probl Surg. 1994;31:253-74.
23. Kim SH, Garcia C, Rodriguez J, Coit DG. Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241-7. (Pubitemid 29113759)
24. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role of lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥ 4mm) primary melanoma. Ann Surg Oncol. 2000;7:160-5. (Pubitemid 30164687)
25. Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001;44:762-6. (Pubitemid 32391162)
26. Singluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg. 1994;219:120-30. (Pubitemid 24064068)
27. Scoggins CR, Bowen AL, Martin 2nd RC, Edwards MJ, Reintgen DS, Ross MI, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145:622-7.
28. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637-45. (Pubitemid 34857980)
29. Mandala M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overallsurvival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45:2537-45.
30. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (> 4mm) primary melanoma. Ann Surg Oncol. 1998;5:322-8. (Pubitemid 28272435)
31. Goeppner D, Ulrich J, Pokrywka A, Peters B, Gollnick H, Leverkus M. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors >4.0 mm. Dermatology. 2011;222:59-66.
32. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452-9.
33. Miller MW, Vetto JT, Monroe MM, Weerasinghe R, Andersen PE, Gross N. False-negative sentinel lymph node biopsy in head and neck melanoma. Otolaryngol Head Neck Surg. 2011;145:606-11.
34. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histological negative sentinel lymph nodes. Arch Surg. 1999;134:381-7. (Pubitemid 29282079)
35. Yudd AP, Kempf JS, Goydos JS, Stahl TJ, Feinstein RS. Use of sentinel node lymphoscintigraphy in malignant melanoma. Radiographics. 1999;19:343-53.
36. Leong SP. Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol. 2011;104:361-8.
37. Pitman KT, Johnson JT, Brown ML, Myers EN. Sentinel lymph node biopsy in head and neck squamous cell carcinoma. Laryngoscope. 2002;112:2101-13. (Pubitemid 35417031)
38. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin primary melanoma. Ann Surg Oncol. 2003;10:558-61. (Pubitemid 40486920)
39. Zapas JL, Coley HC, Beam SL, Brown SD, Jablonski KA, Elias EG. The risk of regional lymph node metastases in patients with melanoma less than 1.0mm thick: recommendation for sentinel lymph node biopsy. J Am Coll Surg. 2003;197:403-7. (Pubitemid 38373299)